Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia
  2. Corresponding author: Kun Zhang, PhD, Division of Overdose Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Hwy, Atlanta, GA 30341 ([email protected]).
  3. National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia
  4. National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland
  5. National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia
  6. National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia
  7. National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland
  1. Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts. Centers for Disease Control and Prevention. 2020. https://www.cdc.gov/nchs/nvss/vsrr/prhttps://www.cdc.gov/nchs/nvss/vsrr/provisional-drug-overdose.htm
  2. Liu S, Scholl L, Hoots B, et al. Nonfatal drug and polydrug overdoses treated in emergency departments—29 States, 2018–2019. MMWR Morb Mortal Wkly Rep. 2020;69(34):1149–1155. PubMed CrossRef
  3. Strategy to Combat Opioid Abuse, Misuse, and Overdose-A Framework Based on the Five Point Strategy. US Department of Health and Human Services. 2018. Accessed May 15, 2020. https://www.hhs.gov/opioids/sites/default/files/2018-09/opioid-fivepoint-strategy-20180917-508compliant.pdf
  4. National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. The National Academies Press; 2019. https://doi.org/10.17226/25310.
  5. Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2(2):CD002207. PubMed CrossRef
  6. Krawczyk N, Mojtabai R, Stuart EA, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction. 2020;115(9):1683–1694. PubMed CrossRef
  7. Tsui JI, Evans JL, Lum PJ, et al. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174(12):1974–1981. PubMed CrossRef
  8. Barocas JA, Gai MJ, Amuchi B, et al. Impact of medications for opioid use disorder among persons hospitalized for drug use-associated skin and soft tissue infections. Drug Alcohol Depend. 2020;215:108207. PubMed CrossRef
  9. Andrilla CHA, Coulthard C, Larson EH. Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Ann Fam Med. 2017;15(4):359–362. PubMed CrossRef
  10. Beetham T, Saloner B, Wakeman SE, et al. Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality: an audit study. Ann Intern Med. 2019;171(1):1–9. PubMed CrossRef
  11. Jones CM, McCance-Katz EF. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction. 2019;114(3):471–482. PubMed CrossRef
  12. Beetham T, Saloner B, Gaye M, et al. Therapies offered at residential addiction treatment programs in the United States. JAMA. 2020;324(8):804–806. PubMed CrossRef
  13. ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. American Society of Addiction Medicine. 2020. https://www.asam.org/Quality-Science/quality/2020-national-practice-guideline
  14. Eastwood B, Strang J, Marsden J. Effectiveness of treatment for opioid use disorder: A national, five-year, prospective, observational study in England. Drug Alcohol Depend. 2017;176:139–147. PubMed CrossRef
  15. Timko C, Schultz NR, Cucciare MA, et al. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis. 2016;35(1):22–35. PubMed CrossRef
  16. Volkow ND, Frieden TR, Hyde PS, et al. Medication-assisted therapies: tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–2066. PubMed CrossRef
  17. Samples H, Williams AR, Crystal S, et al. Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid. Health Aff (Millwood). 2020;39(5):747–755. PubMed CrossRef
  18. Williams AR, Samples H, Crystal S, et al. Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. Am J Psychiatry. 2020;177(2):117–124. PubMed CrossRef
  19. Parran TV, Adelman CA, Merkin B, et al. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010;106(1):56–60. PubMed CrossRef
  20. Daley DC. Family and social aspects of substance use disorders and treatment. Yao Wu Shi Pin Fen Xi. 2013;21(4):S73–S76. PubMed CrossRef
  21. Barry CL, McGinty EE, Pescosolido BA, et al. Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness. Psychiatr Serv. 2014;65(10):1269–1272. PubMed CrossRef
  22. Levin FR, Bisaga A, Sullivan MA, et al. A review of a national training initiative to increase provider use of MAT to address the opioid epidemic. Am J Addict. 2016;25(8):603–609. PubMed CrossRef
  23. Manhapra A, Agbese E, Leslie DL, et al. Three‐year retention in buprenorphine treatment for opioid use disorder among privately insured adults. Psychiatr Serv. 2018;69(7):768–776. PubMed CrossRef
  24. Goldner EM, Lusted A, Roerecke M, et al. Prevalence of Axis-1 psychiatric disorder and symptomatology among non-medical prescription opioid users in substance use treatment: systematic review and meta-analyses. Addict Behav. 2014;39(3):520–531. PubMed CrossRef
  25. Han B, Compton WM, Blanco C, et al. Prescription opioid use, misuse, and use disorders in US adults: 2015 National Survey on Drug Use and Health. Ann Intern Med. 2017;167(5):293–301. PubMed CrossRef
  26. Hasin D, Liu X, Nunes E, et al. Effects of major depression on remission and relapse of substance dependence. Arch Gen Psychiatry. 2002;59(4):375–380. PubMed CrossRef
  27. Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. Biol Psychiatry. 2004;56(10):793–802. PubMed CrossRef
  28. Volkow ND, Jones EB, Einstein EB, et al. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry. 2019;76(2):208–216. PubMed CrossRef
  29. Woody GE, O’Brien CP, McLellan AT, et al. The use of antidepressants with methadone in depressed maintenance patients. Ann N Y Acad Sci. 1982;398:120–127. PubMed CrossRef
  30. Agbese E, Leslie DL, Manhapra A, et al. Early discontinuation of buprenorphine therapy for opioid use disorder among privately insured adults. Psychiatr Serv. 2020;71(8):779–788. PubMed CrossRef
  31. Bunavail (buprenorphine and naloxone). Package insert. BioDelivery Sciences International, Inc. US Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205637s020lbl.pdf#page=31. Revised October 2019. Accessed May 20, 2020.
  32. Suboxone (buprenorphine and naloxone). Package insert. Indivior Inc. US Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022410s038lbl.pdf#page=32. Revised October 2019. Accessed May 20, 2020.
  33. Zubsolv (buprenorphine and naloxone). Package insert. Orexo US, Inc. US Food and Drug Administration website. Revised October 2019. Accessed May 20, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204242s017lbl.pdf#page=18.
  34. Morgan JR, Schackman BR, Leff JA, et al. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90–96. PubMed CrossRef
  35. Samples H, Williams AR, Olfson M, et al. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat. 2018;95:9–17. PubMed CrossRef
  36. Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019;197:78–82. PubMed CrossRef
  37. Friesen EL, Kurdyak P. The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder. Drug Alcohol Depend. 2020;216(1):108244. PubMed CrossRef
  38. Griffin ML, Dodd DR, Potter JS, et al. Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder. Am J Drug Alcohol Abuse. 2014;40(2):157–162. PubMed CrossRef
  39. Substance Abuse and Mental Health Services Administration. Projections of National Expenditures for Treatment of Mental and Substance Use Disorders, 2010–2020. 2014. HHS Publication No SMA-14-4883. Accessed July 2021. https://store.samhsa.gov/sites/default/files/d7/priv/sma14-4883.pdf
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe now